Targeted vaccine selection in influenza vaccination.
Identifieur interne : 000202 ( Main/Exploration ); précédent : 000201; suivant : 000203Targeted vaccine selection in influenza vaccination.
Auteurs : Peter Wutzler ; Roland Hardt ; Markus Knuf ; Klaus WahleSource :
- Deutsches Arzteblatt international [ 1866-0452 ] ; 2013.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Allemagne (épidémiologie), Appréciation des risques (MeSH), Comorbidité (MeSH), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (épidémiologie), Hospitalisation (statistiques et données numériques), Humains (MeSH), Jeune adulte (MeSH), Nourrisson (MeSH), Pneumopathie virale (prévention et contrôle), Pneumopathie virale (épidémiologie), Prévalence (MeSH), Répartition par sexe (MeSH), Répartition par âge (MeSH), Résultat thérapeutique (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Sélection de patients (MeSH), Vaccination de masse (statistiques et données numériques), Vaccins antigrippaux (administration et posologie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- prévention et contrôle : Grippe humaine, Pneumopathie virale.
- statistiques et données numériques : Hospitalisation, Vaccination de masse.
- épidémiologie : Allemagne, Grippe humaine, Pneumopathie virale.
- Adolescent, Adulte, Adulte d'âge moyen, Appréciation des risques, Comorbidité, Enfant, Enfant d'âge préscolaire, Humains, Jeune adulte, Nourrisson, Prévalence, Répartition par sexe, Répartition par âge, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Sélection de patients.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Age Distribution (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Child (MeSH), Child, Preschool (MeSH), Comorbidity (MeSH), Germany (epidemiology), Hospitalization (statistics & numerical data), Humans (MeSH), Infant (MeSH), Influenza Vaccines (administration & dosage), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Mass Vaccination (statistics & numerical data), Middle Aged (MeSH), Patient Selection (MeSH), Pneumonia, Viral (epidemiology), Pneumonia, Viral (prevention & control), Prevalence (MeSH), Risk Assessment (MeSH), Sex Distribution (MeSH), Treatment Outcome (MeSH), Young Adult (MeSH).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- geographic , epidemiology : Germany.
- epidemiology : Influenza, Human, Pneumonia, Viral.
- prevention & control : Influenza, Human, Pneumonia, Viral.
- statistics & numerical data : Hospitalization, Mass Vaccination.
- Adolescent, Adult, Age Distribution, Aged, Aged, 80 and over, Child, Child, Preschool, Comorbidity, Humans, Infant, Middle Aged, Patient Selection, Prevalence, Risk Assessment, Sex Distribution, Treatment Outcome, Young Adult.
Abstract
BACKGROUND
The main target groups for influenza vaccination are the elderly, the chronically ill, infants, and toddlers. Influenza vaccines are needed that suit the immunological particularities of each of these age and risk groups. Recent years have seen the approval of influenza vaccines that are more immunogenic than before, but whose use in Germany is limited by the restriction of reimbursement to a small number of vaccines.
METHODS
The Medline database was selectively searched for pertinent literature.
RESULTS
The suboptimal immunogenicity of conventional influenza vaccines that contain inactivated viral cleavage products and subunits can be markedly improved by the use of squalene-based adjuvant systems, by the integration of viral antigens in virosomal particles, or by intradermal administration. The vaccination of elderly persons with a vaccine containing the adjuvant MF59 was found to lower the risk of hospitalization for influenza or pneumonia by 25% compared to vaccination with a trivalent inactivated vaccine (TIV). On the other hand, the adjuvant ASO3 was found to be associated with an up to 17-fold increase in the frequency of narcolepsy among 4- to 18-year-olds. In a prospective study, a virosomal vaccine lowered the frequency of laboratory-confirmed influenza in vaccinated children by 88% compared to unvaccinated children (2 versus 18 cases per 1000 individuals). A live, attenuated influenza vaccine lowered the rate of disease in children up to age 7 by 48% compared to a TIV (4.2% versus 8.1%).
CONCLUSION
The newer vaccines possess improved efficacy when used for primary and booster immunization in certain age and risk groups, and they are superior in this respect to conventional vaccines based on viral cleavage products and subunits. The risk/benefit profiles of all currently available vaccines vary depending on the age group or risk group in which they are used.
DOI: 10.3238/arztebl.2013.0793
PubMed: 24314622
PubMed Central: PMC3859908
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Targeted vaccine selection in influenza vaccination.</title><author><name sortKey="Wutzler, Peter" sort="Wutzler, Peter" uniqKey="Wutzler P" first="Peter" last="Wutzler">Peter Wutzler</name><affiliation><nlm:affiliation>Institute of Virology and Antiviral Therapy - University Hospital Jena, Catholic Clinic Mainz, St. Hildegardis Hospital, Department of Child and Adolescent Medicine, Dr. Horst Schmidt Clinic GmbH, Wiesbaden, German Association of General Practitioners, Münster.</nlm:affiliation><wicri:noCountry code="subField">Münster</wicri:noCountry></affiliation></author><author><name sortKey="Hardt, Roland" sort="Hardt, Roland" uniqKey="Hardt R" first="Roland" last="Hardt">Roland Hardt</name></author><author><name sortKey="Knuf, Markus" sort="Knuf, Markus" uniqKey="Knuf M" first="Markus" last="Knuf">Markus Knuf</name></author><author><name sortKey="Wahle, Klaus" sort="Wahle, Klaus" uniqKey="Wahle K" first="Klaus" last="Wahle">Klaus Wahle</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:24314622</idno><idno type="pmid">24314622</idno><idno type="doi">10.3238/arztebl.2013.0793</idno><idno type="pmc">PMC3859908</idno><idno type="wicri:Area/Main/Corpus">000175</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000175</idno><idno type="wicri:Area/Main/Curation">000175</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000175</idno><idno type="wicri:Area/Main/Exploration">000175</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Targeted vaccine selection in influenza vaccination.</title><author><name sortKey="Wutzler, Peter" sort="Wutzler, Peter" uniqKey="Wutzler P" first="Peter" last="Wutzler">Peter Wutzler</name><affiliation><nlm:affiliation>Institute of Virology and Antiviral Therapy - University Hospital Jena, Catholic Clinic Mainz, St. Hildegardis Hospital, Department of Child and Adolescent Medicine, Dr. Horst Schmidt Clinic GmbH, Wiesbaden, German Association of General Practitioners, Münster.</nlm:affiliation><wicri:noCountry code="subField">Münster</wicri:noCountry></affiliation></author><author><name sortKey="Hardt, Roland" sort="Hardt, Roland" uniqKey="Hardt R" first="Roland" last="Hardt">Roland Hardt</name></author><author><name sortKey="Knuf, Markus" sort="Knuf, Markus" uniqKey="Knuf M" first="Markus" last="Knuf">Markus Knuf</name></author><author><name sortKey="Wahle, Klaus" sort="Wahle, Klaus" uniqKey="Wahle K" first="Klaus" last="Wahle">Klaus Wahle</name></author></analytic><series><title level="j">Deutsches Arzteblatt international</title><idno type="eISSN">1866-0452</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Age Distribution (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Comorbidity (MeSH)</term><term>Germany (epidemiology)</term><term>Hospitalization (statistics & numerical data)</term><term>Humans (MeSH)</term><term>Infant (MeSH)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Mass Vaccination (statistics & numerical data)</term><term>Middle Aged (MeSH)</term><term>Patient Selection (MeSH)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (prevention & control)</term><term>Prevalence (MeSH)</term><term>Risk Assessment (MeSH)</term><term>Sex Distribution (MeSH)</term><term>Treatment Outcome (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Allemagne (épidémiologie)</term><term>Appréciation des risques (MeSH)</term><term>Comorbidité (MeSH)</term><term>Enfant (MeSH)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (épidémiologie)</term><term>Hospitalisation (statistiques et données numériques)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Nourrisson (MeSH)</term><term>Pneumopathie virale (prévention et contrôle)</term><term>Pneumopathie virale (épidémiologie)</term><term>Prévalence (MeSH)</term><term>Répartition par sexe (MeSH)</term><term>Répartition par âge (MeSH)</term><term>Résultat thérapeutique (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Sélection de patients (MeSH)</term><term>Vaccination de masse (statistiques et données numériques)</term><term>Vaccins antigrippaux (administration et posologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Germany</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term><term>Mass Vaccination</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Hospitalisation</term><term>Vaccination de masse</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term><term>Grippe humaine</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Age Distribution</term><term>Aged</term><term>Aged, 80 and over</term><term>Child</term><term>Child, Preschool</term><term>Comorbidity</term><term>Humans</term><term>Infant</term><term>Middle Aged</term><term>Patient Selection</term><term>Prevalence</term><term>Risk Assessment</term><term>Sex Distribution</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Appréciation des risques</term><term>Comorbidité</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Humains</term><term>Jeune adulte</term><term>Nourrisson</term><term>Prévalence</term><term>Répartition par sexe</term><term>Répartition par âge</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Sélection de patients</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The main target groups for influenza vaccination are the elderly, the chronically ill, infants, and toddlers. Influenza vaccines are needed that suit the immunological particularities of each of these age and risk groups. Recent years have seen the approval of influenza vaccines that are more immunogenic than before, but whose use in Germany is limited by the restriction of reimbursement to a small number of vaccines.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>The Medline database was selectively searched for pertinent literature.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The suboptimal immunogenicity of conventional influenza vaccines that contain inactivated viral cleavage products and subunits can be markedly improved by the use of squalene-based adjuvant systems, by the integration of viral antigens in virosomal particles, or by intradermal administration. The vaccination of elderly persons with a vaccine containing the adjuvant MF59 was found to lower the risk of hospitalization for influenza or pneumonia by 25% compared to vaccination with a trivalent inactivated vaccine (TIV). On the other hand, the adjuvant ASO3 was found to be associated with an up to 17-fold increase in the frequency of narcolepsy among 4- to 18-year-olds. In a prospective study, a virosomal vaccine lowered the frequency of laboratory-confirmed influenza in vaccinated children by 88% compared to unvaccinated children (2 versus 18 cases per 1000 individuals). A live, attenuated influenza vaccine lowered the rate of disease in children up to age 7 by 48% compared to a TIV (4.2% versus 8.1%).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>The newer vaccines possess improved efficacy when used for primary and booster immunization in certain age and risk groups, and they are superior in this respect to conventional vaccines based on viral cleavage products and subunits. The risk/benefit profiles of all currently available vaccines vary depending on the age group or risk group in which they are used.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24314622</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1866-0452</ISSN><JournalIssue CitedMedium="Internet"><Volume>110</Volume><Issue>47</Issue><PubDate><Year>2013</Year><Month>Nov</Month><Day>22</Day></PubDate></JournalIssue><Title>Deutsches Arzteblatt international</Title><ISOAbbreviation>Dtsch Arztebl Int</ISOAbbreviation></Journal><ArticleTitle>Targeted vaccine selection in influenza vaccination.</ArticleTitle><Pagination><MedlinePgn>793-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3238/arztebl.2013.0793</ELocationID><ELocationID EIdType="pii" ValidYN="Y">arztebl.2013.0793</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The main target groups for influenza vaccination are the elderly, the chronically ill, infants, and toddlers. Influenza vaccines are needed that suit the immunological particularities of each of these age and risk groups. Recent years have seen the approval of influenza vaccines that are more immunogenic than before, but whose use in Germany is limited by the restriction of reimbursement to a small number of vaccines.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Medline database was selectively searched for pertinent literature.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The suboptimal immunogenicity of conventional influenza vaccines that contain inactivated viral cleavage products and subunits can be markedly improved by the use of squalene-based adjuvant systems, by the integration of viral antigens in virosomal particles, or by intradermal administration. The vaccination of elderly persons with a vaccine containing the adjuvant MF59 was found to lower the risk of hospitalization for influenza or pneumonia by 25% compared to vaccination with a trivalent inactivated vaccine (TIV). On the other hand, the adjuvant ASO3 was found to be associated with an up to 17-fold increase in the frequency of narcolepsy among 4- to 18-year-olds. In a prospective study, a virosomal vaccine lowered the frequency of laboratory-confirmed influenza in vaccinated children by 88% compared to unvaccinated children (2 versus 18 cases per 1000 individuals). A live, attenuated influenza vaccine lowered the rate of disease in children up to age 7 by 48% compared to a TIV (4.2% versus 8.1%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The newer vaccines possess improved efficacy when used for primary and booster immunization in certain age and risk groups, and they are superior in this respect to conventional vaccines based on viral cleavage products and subunits. The risk/benefit profiles of all currently available vaccines vary depending on the age group or risk group in which they are used.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wutzler</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Virology and Antiviral Therapy - University Hospital Jena, Catholic Clinic Mainz, St. Hildegardis Hospital, Department of Child and Adolescent Medicine, Dr. Horst Schmidt Clinic GmbH, Wiesbaden, German Association of General Practitioners, Münster.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardt</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Knuf</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wahle</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Dtsch Arztebl Int</MedlineTA><NlmUniqueID>101475967</NlmUniqueID><ISSNLinking>1866-0452</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Dtsch Arztebl Int. 2013 Nov 22;110(47):791-2</RefSource><PMID Version="1">24314621</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dtsch Arztebl Int. 2014 Feb 28;111(9):150</RefSource><PMID Version="1">24661589</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dtsch Arztebl Int. 2014 Feb 28;111(9):150</RefSource><PMID Version="1">24661590</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032541" MajorTopicYN="N">Mass Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017678" MajorTopicYN="N">Sex Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>09</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>09</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24314622</ArticleId><ArticleId IdType="pii">arztebl.2013.0793</ArticleId><ArticleId IdType="doi">10.3238/arztebl.2013.0793</ArticleId><ArticleId IdType="pmc">PMC3859908</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vaccine. 2007 Nov 1;25(44):7656-63</Citation><ArticleIdList><ArticleId IdType="pubmed">17913310</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2006 Oct;25(10):860-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17006278</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Feb 15;356(7):685-96</Citation><ArticleIdList><ArticleId IdType="pubmed">17301299</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2000 Mar;181(3):1133-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10720541</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Jan 20;30(5):886-92</Citation><ArticleIdList><ArticleId IdType="pubmed">22155144</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Dec 2;26(51):6614-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18930093</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Nov 19;30(49):7005-12</Citation><ArticleIdList><ArticleId IdType="pubmed">23059357</ArticleId></ArticleIdList></Reference><Reference><Citation>Viral Immunol. 2002;15(2):295-323</Citation><ArticleIdList><ArticleId IdType="pubmed">12081014</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 May 14;30(23):3470-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22446638</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2011 Oct 13;365(15):1406-16</Citation><ArticleIdList><ArticleId IdType="pubmed">21995388</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2004 Dec 2;23(3):283-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15530669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2007 Aug 18;370(9587):580-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17707753</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Sep 12;26 Suppl 4:D10-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18611422</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2002 Dec 20;20 Suppl 5:B24-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12477414</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(3):e33536</Citation><ArticleIdList><ArticleId IdType="pubmed">22470453</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2001 Mar 21;19(17-19):2673-80</Citation><ArticleIdList><ArticleId IdType="pubmed">11257408</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2008 Sep 1;198(5):650-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18652550</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2012 Jan;12(1):36-44</Citation><ArticleIdList><ArticleId IdType="pubmed">22032844</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2012 Sep 15;176(6):527-33</Citation><ArticleIdList><ArticleId IdType="pubmed">22940713</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Immunol. 2007 Sep;27(5):542-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17514499</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 May 16;25(20):3955-61</Citation><ArticleIdList><ArticleId IdType="pubmed">17383057</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Oct 23;27(45):6284-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19856521</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Oct 16;25(42):7313-21</Citation><ArticleIdList><ArticleId IdType="pubmed">17889411</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2013;346:f794</Citation><ArticleIdList><ArticleId IdType="pubmed">23444425</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2003 Feb 1;306(1):18-24</Citation><ArticleIdList><ArticleId IdType="pubmed">12620793</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2011 Mar;30(3):203-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20935591</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Nov 10;24(44-46):6638-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16842892</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Nov 6;30(48):6794-801</Citation><ArticleIdList><ArticleId IdType="pubmed">23000125</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2004 Jul;103(1-2):139-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15163502</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 1997 Oct;15(15):1675-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9364699</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2008;(2):CD004879</Citation><ArticleIdList><ArticleId IdType="pubmed">18425905</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2009 Jul;28(7):563-71</Citation><ArticleIdList><ArticleId IdType="pubmed">19561422</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Apr 16;30(18):2908-13</Citation><ArticleIdList><ArticleId IdType="pubmed">22342501</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2006 May 22;166(10):1121-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16717175</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 2000 Feb;136(2):168-75</Citation><ArticleIdList><ArticleId IdType="pubmed">10657821</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Dev Immunol. 2010;2010:517198</Citation><ArticleIdList><ArticleId IdType="pubmed">20369059</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 Jul 8;23 Suppl 1:S26-38</Citation><ArticleIdList><ArticleId IdType="pubmed">16026906</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2010 Apr 30;59(16):485-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20431524</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2012 May;19(5):638-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22379067</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2010;10:134</Citation><ArticleIdList><ArticleId IdType="pubmed">20504306</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2006 Jul;25(7):590-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16804427</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2011 Sep 15;204(6):845-53</Citation><ArticleIdList><ArticleId IdType="pubmed">21846636</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Apr 5;29(16):2865-73</Citation><ArticleIdList><ArticleId IdType="pubmed">21352939</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Sep 7;28 Suppl 4:D45-53</Citation><ArticleIdList><ArticleId IdType="pubmed">20713260</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006 Mar;49(3):287-95</Citation><ArticleIdList><ArticleId IdType="pubmed">16465515</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2010;(7):CD001269</Citation><ArticleIdList><ArticleId IdType="pubmed">20614424</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Infect Dis. 2011 Sep;43(9):702-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21534891</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontology. 2003 May-Jun;49(3):177-84</Citation><ArticleIdList><ArticleId IdType="pubmed">12679609</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2006 Oct;25(10):870-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17006279</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Nov 15;29(49):9159-70</Citation><ArticleIdList><ArticleId IdType="pubmed">21840359</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Dec 14;30(52):7439-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23088885</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Drug Investig. 1998;15(1):1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">18370460</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Apr 12;24(16):3063-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16464520</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Jun 19;26(26):3197-208</Citation><ArticleIdList><ArticleId IdType="pubmed">18486285</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2010 May 1;4(3):141-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20409210</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Nov 10;24(44-46):6629-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16901593</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2011 Jan;11(1):23-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21106443</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2008 Oct;7(8):1201-14</Citation><ArticleIdList><ArticleId IdType="pubmed">18844594</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2013 Jan 30;31(6):861-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23261045</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(3):e33723</Citation><ArticleIdList><ArticleId IdType="pubmed">22470463</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2002 Aug 19;20(25-26):3068-87</Citation><ArticleIdList><ArticleId IdType="pubmed">12163258</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Hardt, Roland" sort="Hardt, Roland" uniqKey="Hardt R" first="Roland" last="Hardt">Roland Hardt</name><name sortKey="Knuf, Markus" sort="Knuf, Markus" uniqKey="Knuf M" first="Markus" last="Knuf">Markus Knuf</name><name sortKey="Wahle, Klaus" sort="Wahle, Klaus" uniqKey="Wahle K" first="Klaus" last="Wahle">Klaus Wahle</name><name sortKey="Wutzler, Peter" sort="Wutzler, Peter" uniqKey="Wutzler P" first="Peter" last="Wutzler">Peter Wutzler</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000202 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000202 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeAllemagneV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24314622
|texte= Targeted vaccine selection in influenza vaccination.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24314622" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV4
| This area was generated with Dilib version V0.6.35. |  |